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rginine and Old MACE
mall Molecules in Atherogenesis
upport the Concept of Coronary
rtery Disease as a Complex Trait*
ichard I. Levin, MD
ontreal, Quebec, Canada
n the final years of the last century, the noted epidemiol-
gist Meir Stampfer proclaimed that over 90% of coronary
rtery disease (CAD) could be prevented. This was not an
dle rumination but a prediction based on his own work
1,2) and the remarkable development of knowledge on
therogenesis and acute coronary syndromes (ACS) since
orld War II. Coronary artery disease had been demon-
trated to be an inflammatory illness, due to chronic vascular
xposure to oxidized lipids and other endothelial toxins,
hose plaques could rupture and trigger thrombosis, acutely
mpeding myocardial blood flow and causing ACS (3–5). At
he same time that surgical and percutaneous interventional
pproaches were being perfected, the field was being focused
n biologic interventions that would reduce vascular inflam-
ation and prevent complications if not cure atherosclero-
is. The unified theory is the basis for Stampfer’s prediction,
nd it is likely true.
See page 2061
But at the beginning of the “Century of Biology,”
therosclerosis might not be your father’s steak, eggs, and an
arly morning smoke. Hyperlipidemia and inflammation
ight play a duet, each leading to atherogenesis (6) with the
ffective treatment of either, for example, in the setting of
normal” low-density lipoprotein cholesterol levels (130
g/dl), improving outcomes (7). The pathology and clini-
al expression also might be binary, with thick-capped,
ipid-poor, constrictive plaques causing chronic ischemia
nd thin-capped, lipid-rich, less-intrusive plaques causing
CS (8). And the importance of family history for “prema-
ure” ACS (9) might not lie in genes for atherogenesis but
n genes for myocardial infarction itself (10,11). The con-
ept that there could be separate inheritance for atheroscle-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.f
From the Department of Medicine, Division of Cardiology, and the Office of the
ean, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.osis on the one hand and myocardial infarction on the
ther is one of the foundation-crumbling wonders of the
enomic age, as shocking as the tiny number of human
rotein-encoding genes and the Lamarckian appearance of
pigenetics.
Modern molecular biology has also enhanced knowledge
f atherosclerosis along more exotic pathways. In the 1950s,
notion was popularized that atherosclerosis was due to
slow metabolism,” perhaps on the basis of the theory that
low clearance of postprandial lipids allowed fatty arterial
eposits to grow (12). Metabolism and small molecular
odifications outside of the traditional risk factors—
lthough all operating along the inflammatory-atherogenic-
hrombotic axis—now have been identified as important in
therosclerosis as well. These moieties cover quite a spec-
rum and include advanced glycation end products and their
eceptor (13,14), arginase I in macrophages (15), and
rotein carbamylation (16). The latter work of Wang et al.
16), some of whom are coauthors on the present study (13),
s an important set of observations linking smoking and
remia to atherogenesis through inflammation induced by
omocitrulline modification of proteins by cyanate (13).
It is in this remarkable and heightened environment of
iscovery that Tang et al. (17) at the Cleveland Clinic
escribe a possible role for the catabolism of the amino acid
rginine in both atherosclerosis and major adverse cardio-
ascular events (MACE). Arginine is the sole source of
itrogen for the synthesis of nitric oxide (NO), a former
olecule of the year (18), which has broad biologic signal-
ng activities, is a potent vasodilator, and is protective of the
asculature (19). The authors hypothesized that a sensitive
pproach to measuring arginine and its catabolites, orni-
hine and citrulline, in the NO synthetic pathway (see Fig.
in Tang et al. [17]) would show that atherosclerosis and
ACE are related to decreased arginine bioavailability.
ecreased bioavailability could limit NO, and this in turn
ould diminish its protection of the vasculature, allowing
therogenesis to flourish. They measured the “global argi-
ine bioavailability ratio” (GABR), defined as arginine/
ornithine  citrulline), as that sensitive measure, more
ensitive than measuring arginine levels alone. The study
sed 1,010 consecutive subjects undergoing elective cardiac
atheterization who had been enrolled in a sophisticated
issue-banking protocol that included plasma, serum, and
eoxyribonucleic acid. They discovered, after adjusting for
onfounders, that both decreased GABR and higher con-
entrations of citrulline were correlated with the prevalence
f CAD (with adjusted odds ratios of 3.93 and 5.98,
espectively) and the development of MACE (with adjusted
azard ratios of 1.98 and 2.40, respectively) (17). The
elationships are strong, the study is interesting, and the
uthors have described another small molecule that might
ave atherogenic and plaque-disrupting potential.
We do not know, on the basis of this first analysisocusing on the substrates of the NO synthetic pathway,
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June 2, 2009:2068–9 Arginine, NO, and CAD as a Complex Traithether GABR or citrulline alone will prove to be either
echanistically important in atherogenesis or predictive of
ACE as a biomarker. The kinetics and compartmental-
zation of NO synthesis (20) make the significance of a low
ABR or a high citrulline concentration uncertain, in the
mportant terms of whether they result in poor or inade-
uate or inappropriate synthesis of NO, which in turn could
ead to atherogenesis and MACE. As for the establish-
ent of GABR as a prognostic factor, as the authors point
ut, a prospective study across a broader population will be
ecessary.
Nonetheless, this work adds importantly to the rich
nderstanding of CAD as a “complex trait,” defined rather
icely by a workshop at the National Institutes of Health as
determined by many factors, including genetic and envi-
onmental components, which interact in often unpredict-
ble ways [wherein. . .] the whole is not only greater than
he sum of its parts, it might be different from the sum of its
arts” (21). We still do not know whether, if the popula-
ion had a low-density lipoprotein cholesterol level of 70
g/dl, around which endothelial-dependent relaxation
eaches a maximum, or one even lower, there would be any
therosclerosis at all. Whereas CAD might become the
eading cause of death in the world in a few years, the secrets
f its complexity will continue to unfold, and ultimately
tampfer’s prediction will prevail.
eprint requests and correspondence: Dr. Richard I. Levin,
ffice of the Dean, Faculty of Medicine, McGill University, 3605
e la Montagne, Montreal, Quebec H3G 2M1, Canada. E-mail:
ichard.levin@mcgill.ca.
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